COMMUNIQUÉS West-GlobeNewswire

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026
09/12/2025
Continues to drive enrollment with increase to 78% now consented Blinded response activity tracking within expected range Consented subjects now across seven countries supporting the expansion of the MIRACLE trial [...]
FOXO Technologies Inc. Subsidiary, Myrtle Recovery Centers, Recognized by the Rural Health Association of Tennessee for Outstanding Community Impact
09/12/2025
WEST PALM BEACH, FL, Dec. 09, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXO) (“FOXO” or the “Company”) today announced that its behavioral health subsidiary, Myrtle Recovery Centers, Inc., was recently [...]
STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 — Reports Early Adoption Momentum in Mexico
09/12/2025
HORSHAM, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies, announces its participation in the 2025 Ibero-Latin American Congress of [...]
Cuprina Holdings (Cayman) Limited Announces Financial Results for the Six Months Ended June 30, 2025, and Strategic Initiatives for 2026 Growth
09/12/2025
SINGAPORE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited ( Nasdaq: CUPR ) (“ Cuprina ” or “ the Company ”), a biomedical company developing and marketing products for the chronic wounds, [...]
A.D.A.M. Innovations Announces the Launch of ALUNAÉ
09/12/2025
The World’s First AI Genomic-Based Skincare Line Designed to Address Japanese and Asian Environmental Skin Aging TOKYO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- A.D.A.M. Innovations Co. (Japanese corporate name: Genesis [...]
Pluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional Investment
09/12/2025
Weinstein brings a global track record of transforming companies through value unlocking, and participation in over 20 M&A transactions and more than $ 5 billion in exits across healthcare, biotechnology, and [...]
Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
09/12/2025
Financing from new and existing healthcare focused investors The proceeds are expected to extend the Company’s cash runway into Q1 2027, with potential inflection points anticipated in its clinical programs during that [...]
Cannabix Marijuana Breath Test Clears Key Regulatory Milestone: Handheld Breath Collection Unit (BCU) Passes FCC Electronic Emissions Testing
09/12/2025
VANCOUVER, British Columbia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) is pleased to announce that the Cannabix Breath Collection [...]
Cedar Gate Introduces Next-Generation Solutions for Prospective Bundled Payment Models
09/12/2025
GREENWICH, Conn., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Cedar Gate Technologies (Cedar Gate), an IQVIA business and a leader in value-based care technology with over 40 years of experience in bundled payments, has launched [...]
Clene to Present at the Emerging Growth Conference
09/12/2025
SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company [...]
Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer
09/12/2025
Data highlights the ability of Akari’s Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest survival rates The K- [...]
Novo Nordisk has completed its acquisition of Akero Therapeutics
09/12/2025
Bagsværd, Denmark and South San Francisco, CA, US, 9 December 2025 – Novo Nordisk and Akero Therapeutics Inc. (“Akero”) (Nasdaq: AKRO) today announced that Novo Nordisk’s acquisition of Akero, announced on 9 October [...]
Zelluna ASA: Cancellation of subsequent repair offering
09/12/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. [...]
Osivax Completes Enrollment in Phase 2b Asuniva Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate OVX836
09/12/2025
Target enrollment of 2,850 healthy volunteers completed across multiple European countries Topline data read-out expected by mid-2026, subject to influenza circulation during the winter season Lyon, France and Liège, [...]
European Commission approves Roche’s Gazyva/Gazyvaro for adults with active lupus nephritis
09/12/2025
Approval based on phase II NOBILITY and phase III REGENCY studies showing superiority of Gazyva/Gazyvaro over standard therapy alone 1,2 Gazyva/Gazyvaro is the only anti-CD20 antibody to demonstrate a benefit in a [...]
Roche launches new PCR test to help improve diagnostic accuracy for women affected by vaginitis in countries following the CE Mark
09/12/2025
The new PCR test aids in the diagnosis of infectious causes of vaginitis through the detection of bacteria associated with bacterial vaginosis and yeast associated with candida vaginitis. The test will help improve [...]
OSE Immunotherapeutics dévoile son plan stratégique 2026 - 2028 axé sur quatre leviers de création de valeur
09/12/2025
OSE Immunotherapeutics dévoile son plan stratégique 2026 - 2028 axé sur quatre leviers de création de valeur Finalisation de la phase 3 de Tedopi® dans le cancer du poumon non à petites cellules Une ou deux nouvelles [...]
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation
09/12/2025
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation Completion of Tedopi’s phase 3 in Non-Small Cell Lung Cancer One or two new rare/specialty indications for Lusvertikimab [...]
Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma
09/12/2025
Progression free survival (PFS) of 74% at 16 months compares favourably to standard of care PFS of 50% at 11.5 months 1 Strong PFS consistent across key subgroups Reaffirms selection of iSCIB1+ and target HLA population [...]

Pages